CA - FDA chief sees no reason for delay in cannabis rescheduling
2024-04-11 15:38:27 ET
More on Ayr Wellness, Trulieve Cannabis, etc.
- Tilray Brands, Inc. (TLRY) Q3 2024 Earnings Call Transcript
- Tilray Brands Q3 Earnings: Another Disappointing Quarter
- Tilray Could Break Down
- Tilray guidance cut sends cannabis stocks lower
- Tilray GAAP EPS of -$0.12 misses by $0.07, revenue of $188.3M misses by $10.03M